Vitrectomy Without Internal Limiting Membrane Removal in the Treatment of Diffuse Diabetic Macular Edema: a Comparative Kenalog Vs Bevacizumab Intravitreal Injection Vs Control Study
- Sponsor
- Asociación para Evitar la Ceguera en México
- Study ID
- NCT00600301
- Phase
- PHASE3
- Status
- Withdrawn
Conditions
- Diffuse Diabetic Macular Edema
Eligibility Criteria
- Sex
- ALL
- Age
- 20 Years - 90 Years
- Healthy Volunteers
- Not accepted
Interventions
Study Details
Diabetic macular edema is the most common cause of visual loss among patients with diabetic retinopathy. Pars plana vitrectomy has been reported to be effective for the treatment of diabetic macular edema. Previous report showed a limited improvement in visual acuity and macular thickness posterior intraoperative triamcinolone acetonide. Bevacizumab intravitreal injection has been proven be effective in the treatment of diabetic macular edema, in recent publications. The purpose of this study is to evaluate whether vitrectomy with and without intravitreal triamcinolone acetonide and bevacizumab injection affects vision outcome and macular thickness in patients with diabetic macular edema.
Key Dates
- First listed
- Jan 24, 2008
- Start date
- Jan 31, 2008
- Status verified
- May 2024
- Primary completion
- Jan 31, 2008
- Completion
- Jan 31, 2008
Study Design
- Enrollment
- 0 participants (actual)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT